Fly News Breaks for September 23, 2019
Sep 23, 2019 | 05:04 EDT
After hosting meetings with management, Piper Jaffray analyst JP McKim believes DexCom (DXCM) remains "a must own for investors." First off, the analyst does not believe the company was "walking down" numbers at a recent investor conference. Continuous glucose monitoring demand remains "robust" and importantly, G7 is only 12-15 months away, McKim tells investors in a research note. The analyst also left the meetings "with a lot more bullishness" on the hospital market as well as the non-intensive Type 2 market, where he believes DexCom's sensor technology will have an impact. McKim does expect share volatility around the near-term approval of Abbott's (ABT) Libre 2.0 with integrated continuous glucose monitoring, but he believes the impact DexCom "will be short lived in nature." McKim keeps an Overweight rating on the shares with a $182 price target. The stock closed Friday down 59c to $154.40.
News For DXCM;ABT From the Last 2 Days
Feb 18, 2020 | 09:40 EST
Unusual total active option classes on open include: Franklin Resources (BEN), Pretium Resources (PVG), Inovio (INO), WWE (WWE), Abbott (ABT), Wal-Mart (WMT), Berkshire Hathaway (BRK/B), U.S. Natural Gas Fund (UNG), Barrick Gold (GOLD), and GDXJ (GDXJ).
Feb 18, 2020 | 07:46 EST
Abbott announced it has received CE Mark for the new Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal heart rhythms and heart failure. The devices offer new opportunities for patient engagement and remote monitoring through new smartphone connectivity and connected applications. Additional benefits include a patient preferred design, improved battery longevity and MRI compatibility.